Redbiotec is a private biotech company in Zurich-Schlieren. Founded in 2006 as a spin-off of ETH Zürich, the company has won several awards, including the renowned W.A. de Vigier Award.
In 2015, Pfizer acquired Redvax (a Redbiotec spin-off) for its CMV vaccine program and technology platform. Redbiotec has also closed deals with other global industry partners.
Redbiotec is backed by experienced institutional and private investors. Key investors include Zürcher Kantonalbank – Switzerland’s largest cantonal bank with S&P AAA credit rating since 1994, and Redalpine Capital, a European seed and early-stage venture investor.
Selected industry and academic partners:
- Daiichi Sankyo
- Merck Sharp & Dohme
- BIA Separations
- GE Healthcare
- Merck Millipore
- ETH Zürich
- German Cancer Research Center
- University College Cork
- University of Zürich
We actively evaluate partnership opportunities, and welcome you to contact us for further discussion.
We are committed to developing the best engineered microorganisms and proteins to serve unmet patient needs.
Respect and challenge
We respect and we challenge our competitors, employees, partners and shareholders alike.
Teamwork and constructive criticism
Our people build Redbiotec. We value teamwork as much as being critical individuals.